Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?

被引:21
作者
Mandal, Raju Kumar
Mittal, Rama Devi
机构
[1] Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Uttar Pradesh
关键词
Polymorphism; Prostate cancer; BLADDER-CANCER; MDM2; POLYMORPHISMS; BREAST-CANCER; P53; CARCINOMA; FAS; PROTEINS; WOMEN; DNA;
D O I
10.1016/j.urolonc.2010.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Prostate cancer (CaP) is a heterogeneous, multifactorial, and multifocal disease. Therefore, the search for a combination of functional polymorphisms using cell cycle and apoptotic genes as tumor markers is fundamental for a more precise and reliable diagnosis. In the present study, we investigated the diagnostic value of 3 different genes associated with CaP carcinogenesis, encoding for cell cycle (MDM2, CCNDI) and apoptotic (Fas) genes that are differentially expressed in CaP. Methods: In a hospital-based case control study of northern India, blood samples were obtained from 192 CaP patients and 224 cancer-free age matched unrelated healthy controls of similar ethnicity. They were genotyped for MDM2 G309T, CCNDI G870A, Fas A670G, and G1377A polymorphisms using polymerase chain restriction fragment length polymorphism (PCR-RFLP) method. Results: MDM2 30900 variant was at reduced risk for developing CaP (P = 0.041; OR, 0.59). Whereas CCNDI AA genotype demonstrated increased risk (P = 0.018; OR. 1.86). The diplotype analysis of Fas G670A and G1377A (G-A) was observed to be associated with a significant increase in CaP risk (P = 0.024; OR, 1.63). Conclusion: Findings based on current sample size our results suggested a positive association of CCNDIAA genotype and diplotype analysis of Fas G670A and G1377A (G-A) to be associated with CaP risk that could influence the pathophysiology, thereby modulating the risk of CaP. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:555 / 561
页数:7
相关论文
共 31 条
[1]  
BETTICHER DC, 1995, ONCOGENE, V11, P1005
[2]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[3]   Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population [J].
Driver, Kristy E. ;
Song, Honglin ;
Lesueur, Fabienne ;
Ahmed, Shahana ;
Barbosa-Morais, Nuno L. ;
Tyrer, Jonathan P. ;
Ponder, Bruce A. J. ;
Easton, Douglas F. ;
Pharoah, Paul D. P. ;
Dunning, Alison M. .
CARCINOGENESIS, 2008, 29 (02) :333-341
[4]   PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING [J].
GLEASON, DF ;
MELLINGE.GT .
JOURNAL OF UROLOGY, 1974, 111 (01) :58-64
[5]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[6]   The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma [J].
Hong, Y ;
Miao, XP ;
Zhang, XM ;
Ding, F ;
Luo, AP ;
Guo, YL ;
Tan, W ;
Liu, ZH ;
Lin, DX .
CANCER RESEARCH, 2005, 65 (20) :9582-9587
[7]  
Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO
[8]  
2-B
[9]   MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility:: Evidence from 21 case-control studies [J].
Hu, Zhibin ;
Jin, Guangfu ;
Wang, Lu ;
Chen, Feng ;
Wang, Xinru ;
Shen, Hongbing .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (12) :2717-2723
[10]   Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene [J].
Huang, QR ;
Morris, D ;
Manolios, N .
MOLECULAR IMMUNOLOGY, 1997, 34 (8-9) :577-582